Cisplatin liposomal - ALZA

Drug Profile

Cisplatin liposomal - ALZA

Alternative Names: SPI 077; SPI 77

Latest Information Update: 16 Apr 2004

Price : $50

At a glance

  • Originator ALZA Corporation
  • Class Antineoplastics; Platinum complexes
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 16 Apr 2004 Discontinued - Phase-II for Non-small cell lung cancer in USA (unspecified route)
  • 23 Jul 2001 A phase II study has been added to the Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top